<DOC>
	<DOCNO>NCT00800592</DOCNO>
	<brief_summary>The objective study ass safety , tolerability pharmacokinetics intravenous sildenafil ( 10 mg ) administer bolus injection patient Pulmonary Arterial Hypertension already receive stable oral Revatio 20 mg TID .</brief_summary>
	<brief_title>Sildenafil IV Bolus Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Subjects ( â‰¥18 year old ) receive oral Revatio 20 mg TID PAH within approve indication ( EU Summary Product Characteristics ) minimum 1month , investigator 's opinion , demonstrate good tolerability . Subjects PAH nil mouth reason ( eg , elective surgery medical procedure , TPN feeding , gastrointestinal disturbance etc ) may also include study provide haemodynamically stable ( see Inclusion Criterion 4 ) 6 hour period blood pressure pulse monitoring study interfere plan medical surgical intervention . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . Subjects willing able comply schedule visit , treatment plan study test procedure . Any subject receiving Revatio outside ( 'offlabel ' ) current Summary Product Characteristics ( SmPC ) . Other severe acute chronic medical psychiatric condition may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . Introduction potent CYP 3A4 inhibitor ( eg , ketoconazole , itraconazole ritonavir ) within previous 1 month screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sildenafil , Revatio , PAH , IV , Bolus</keyword>
</DOC>